权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

I-Corps: High Throughput Single Cell Assay Platforms

I-Corps：高通量单细胞检测平台

基本信息

批准号：
1439409
负责人：
Euisik Yoon
金额：
$ 5万
依托单位：
Regents of the University of Michigan - Ann Arbor
依托单位国家：
美国
项目类别：
Standard Grant
财政年份：
2014
资助国家：
美国
起止时间：
2014-05-01 至 2015-10-31
项目状态：
已结题

来源：
https://www.nsf.gov/awardsearch/showAward?AWD_ID=1439409&HistoricalAwards=false
关键词：
Corps Throughput Single Cell Assay

项目摘要

This project aims to commercialize high-throughput single cell assay chips for cancer drug screening and modeling of cancer metastasis. Cancer is one of leading causes of death in many developed countries, and cancer metastasis accounts for 90% of the death caused by cancer. Conventional methods for studying metastasis are limited by low throughput or poor relevance to in-vivo microenvironment. There is an unmet need to develop in-vitro devices which can emulate critical steps of the metastatic cascade. In addition to the in-vitro cancer metastasis modeling, the proposed work aims to provide the solution to monitor and analyze cancer cell heterogeneity. Cancer drug resistance is one of the greatest challenges in cancer treatments. The conventional drug development methods used to focus on average drug efficacy and cannot target the drug resistant tumor cells in the whole tumor, which may lead to the relapse of tumor. The presented prototype platforms in this application provide the capability of high-throughput assays at single cell resolution, which can shift the paradigm of cancer research and cancer treatment. The proposed platforms also enable high-throughput screening and in-vitro metastasis emulation, resulting in significant reduction in drug development cost. The proposed platform technology can facilitate the development of novel therapeutic ideas with lower assay cost at high throughput. The proposed devices have a high commercial potential by meeting the need to realize high-throughput low-cost assays for cancer drug development and screening in research communities as well as pharmaceutical companies.

该项目旨在将高通量单细胞分析芯片商业化，用于癌症药物筛选和癌症转移的建模。癌症是许多发达国家的主要死亡原因之一，癌症转移占癌症死亡的90%。传统的研究转移的方法受到吞吐量低或与体内微环境相关性差的限制。有一种尚未得到满足的需求，即开发能够模拟转移级联的关键步骤的体外设备。除了体外肿瘤转移模型外，这项工作还旨在提供监测和分析癌细胞异质性的解决方案。癌症耐药性是癌症治疗中最大的挑战之一。传统的药物开发方法侧重于平均药效，不能针对整个肿瘤的耐药肿瘤细胞，这可能会导致肿瘤的复发。该应用中提出的原型平台提供了单细胞分辨率的高通量分析能力，这将改变癌症研究和癌症治疗的范式。建议的平台还实现了高通量筛选和体外转移模拟，从而显著降低了药物开发成本。所提出的平台技术可以以较低的检测成本和高通量促进新的治疗想法的开发。拟议的设备具有很高的商业潜力，可以满足研究界和制药公司实现高通量、低成本的抗癌药物开发和筛查的需要。